8-K

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OFTHE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported):  April 27, 2018 (April 26, 2018)

CHEMBIO DIAGNOSTICS, INC.

(Exact name of registrant as specified in its charter)

Nevada	0-30379	88-0425691
(State or other jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification Number)

3661 Horseblock Road

Medford, NY 11763

(Address of principal executive offices)

631-924-1135

(Registrant’s Telephone Number)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company           ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

ITEM 7.01. REGULATION FD DISCLOSURE.

On April 26, 2018, the Company issued a press release entitled “Chembio Diagnostics to Report First Quarter 2018 Financial Results on May 9, 2018”.  A copy of the press release is provided herewith as Exhibit 99.1.

ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS

Exhibits.

99.1 Press Release entitled “Chembio Diagnostics to Report First Quarter 2018 Financial Results on May 9, 2018” dated April 26, 2018.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

April 27, 2018	Chembio Diagnostics, Inc.
	By:	/s/ John J. Sperzel III
		John J. Sperzel III
		Chief Executive Officer

EXHIBIT INDEX

Exhibit Number	Description
99.1	Press Release entitled “Chembio Diagnostics to Report First Quarter 2018 Financial Results on May 9, 2018” dated April 26, 2018.

EX-99.1

Exhibit 99.1

Chembio Diagnostics to Report First Quarter 2018 Financial Results on May 9, 2018

MEDFORD, NY, April 26, 2018 -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leader in point-of-care diagnostic tests for infectious diseases, announced today that it will release financial results for the first quarter 2018 after the close of trading on Wednesday, May 9, 2018.  The Company’s management team will host a corresponding conference call beginning at 4:30 pm ET.

Investors interested in listening to the conference call may do so by dialing 877-407-0778 from the US or 201-689-8565 from outside the US.  A live and archived webcast of the event will be available on the “Investors” section of the Company’s website at www.chembio.com.  A telephone replay will be available by dialing 877-481-4010 from the US or 919-882-2331 from outside the US using passcode 28132 until 4:30pm ET on Wednesday, May 16, 2018.

Contact:

Lynn Pieper Lewis

Gilmartin Group

Investor Relations

(415) 937-5402

investor@chembio.com